Hyperphosphatemia

Iron-Based Binder Improves Phosphorus, FGF-23, and Anemia

Iron-Based Binder Improves Phosphorus, FGF-23, and Anemia

By

Clinicians were able to reduce doses of erythropoiesis-stimulating agents and intravenous iron.

Hyperphosphatemia May Increase In-Hospital Mortality

Hyperphosphatemia May Increase In-Hospital Mortality

By

Patients with serum phosphate levels of 4.9 mg/dL or higher upon admission had the worst survival.

Blood Draw Timing May Affect Hyperphosphatemia Management

Blood Draw Timing May Affect Hyperphosphatemia Management

By

Midweek serum phosphate levels can differ from levels measured after a weekend.

Non-Calcium Phosphate Binders May Reduce FGF-23

Non-Calcium Phosphate Binders May Reduce FGF-23

By

Median intact FGF-23 significantly fell by 64% over 1 year of treatment with sucroferic oxyhydroxide or sevelamer.

Nicotinic Acid May Improve Hyperphosphatemia in HD

Nicotinic Acid May Improve Hyperphosphatemia in HD

By

Meta-analysis shows that nicotinic acid could be a good alternative or add on to traditional phosphate binders, but it is associated with a high rate of adverse events.

Phosphate Binder Linked With Reduced Mortality

Phosphate Binder Linked With Reduced Mortality

By

In a meta-analysis, hemodialysis patients using lanthanum carbonate to lower phosphorus levels had a 55% decreased risk of death compared with those taking other binders.

Intensive Phosphate Control May Reduce FGF23 in HD

Intensive Phosphate Control May Reduce FGF23 in HD

By

A serum phosphate control target of 4.5 mg/dL or below in hemodialysis patients was accompanied by a decline in fibroblast growth factor 23.

Phosphate Binders Do Not Interfere With Vitamin D Therapy

Phosphate Binders Do Not Interfere With Vitamin D Therapy

By

Mean 25-hydroxyvitamin D levels did not differ significantly among groups receiving phosphate binders or dietary therapy.

Intensive Phosphorus-Lowering May Reduce PTH

Intensive Phosphorus-Lowering May Reduce PTH

By

In a study, intact parathyroid hormone levels fell by nearly 10% over 6 months in hemodialysis patients who received intensive treatment for hyperphosphatemia.

Dialysis Patients Exhibit Abnormal Postprandial Mineral Handling

Dialysis Patients Exhibit Abnormal Postprandial Mineral Handling

By

Excess calcium following a meal may be deposited in soft tissue and blood vessels, researchers hypothesize.

Iron-Based Binder May Have Advantages Over Sevelamer

Iron-Based Binder May Have Advantages Over Sevelamer

By

Sucroferric oxyhydroxide and sevelemer are similarly effective in lower phosphorus levels in dialysis patients, but the former is associated with less toxicity and lower pill burden.

Sucroferric Oxyhydroxide Improves Phosphorus Control in PD

Sucroferric Oxyhydroxide Improves Phosphorus Control in PD

By

In addition, average phosphate binder pill burden decreased by more than half.

CKD-MBD Guideline Synopsis Issued

CKD-MBD Guideline Synopsis Issued

By

Panel focuses on diagnosing and testing of CKD-MBD and treatment of the CKD-MBD that emphasizes decreasing phosphate, maintaining calcium, and addressing elevated PTH in adults with CKD stage G3a to G5.

Coronary Artery Calcification Risk Factors in CKD Identified

Coronary Artery Calcification Risk Factors in CKD Identified

By

Abnormal calcium-phosphate metabolism appears to be an important pathogenic factor in the development of vascular calcification in patients with chronic kidney disease.

Phosphorus Content Higher in Packaged Meats Listing Phosphate Additives

Phosphorus Content Higher in Packaged Meats Listing Phosphate Additives

By

Additives in packaged meat, poultry, and fish can contribute significantly to the dietary phosphorus and potassium loads in CKD patients, researchers say.

Phosphorus Control by Dietary Restriction May Lead to Malnutrition

Phosphorus Control by Dietary Restriction May Lead to Malnutrition

By

The use of phosphate binders to manage hyperphosphatemia in maintenance hemodialysis patients might allow diets less restricted in protein and calories, according to a study.

Sucroferric Oxyhydroxide Efficacy Similar to That of Sevelamer

Sucroferric Oxyhydroxide Efficacy Similar to That of Sevelamer

By

Serum phosphorus fell to similar levels in two-thirds of peritoneal dialysis patients, but sucroferric oxyhdroxide recipients had a lower pill burden.

Niacin's Phosphate-Lowering Ability Modest

Niacin's Phosphate-Lowering Ability Modest

By

In a study of patients with chronic kidney disease and cardiovascular disease, niacin therapy lowered serum phosphate by just 0.25 mg/dL over 3 years compared with placebo.

Phosphate Binder Use Tied With Better Survival

Phosphate Binder Use Tied With Better Survival

By

Phosphate binder use is associated with a 25% and 37% decreased risk of death from infection-related causes and all-causes, respectively, compared with non-users.

Reducing Phosphorus Improves Survival

Reducing Phosphorus Improves Survival

By

Achieving a phosphate value of 1.4 mmol/L seemed optimal.

Phosphate Binder Reduces FGF23 in CKD Patients

Phosphate Binder Reduces FGF23 in CKD Patients

By

Patients with non-dialysis chronic kidney disease and iron deficiency anemia treated with ferric citrate experienced significant declines in FGF23 regardless of change in serum phosphorus.

In-Hospital Mortality Linked to High, Low Phosphorus

In-Hospital Mortality Linked to High, Low Phosphorus

By

Admission serum phosphorus levels below 2.5 and 4.9 mg/dL and above are associated with increased odds of dying in the hospital.

Sucroferric Oxyhydroxide Improves Phosphorus Control

Sucroferric Oxyhydroxide Improves Phosphorus Control

By

After switching to sucroferric oxyhydroxide, a higher proportion of patients achieved in-range serum phosphorus levels.

Distinct Phosphate Targets Feasible, Pilot Study Shows

Distinct Phosphate Targets Feasible, Pilot Study Shows

By

A randomized controlled pilot study demonstrated the feasibility and safety of performing a large clinical trial that is powered to establish whether phosphate lowering reduces fatal and nonfatal cardiovascular events.

High Phosphorus Ups Risk of Kidney Transplant Failure, Death

High Phosphorus Ups Risk of Kidney Transplant Failure, Death

By

Each 1-mg/dL increase in serum phosphorus among kidney transplant recipients is associated with 36% and 21% increased risk in graft failure and death, respectively.

Sevelamer Carbonate Improves Pediatric Hyperphosphatemia

Sevelamer Carbonate Improves Pediatric Hyperphosphatemia

By

Phase 2 randomized placebo-controlled trial demonstrated the safety and efficacy of sevelamer in lowering serum phosphorus levels in children and adolescents.

Sodium Phosphate Enemas Do Not Worsen Renal Function

Sodium Phosphate Enemas Do Not Worsen Renal Function

By

Creatinine, phosphorus, and electrolyte levels were not significantly different for exposed and unexposed hospitalized patients.

Nutritional Status Affects Phosphorus-Mortality Link in Hemodialysis

Nutritional Status Affects Phosphorus-Mortality Link in Hemodialysis

By

New findings suggest that nutritional index should be considered in the management of phosphorus level in HD patients, researchers conclude.

Researchers: Iron-based Binders Best for Hyperphosphatemia

Researchers: Iron-based Binders Best for Hyperphosphatemia

By

Of 7 phosphate binders, iron-based agents were optimal when efficacy and safety are considered.

Adynamic Bone Disease Prevalent in Type 2 Diabetes Patients With CKD

Adynamic Bone Disease Prevalent in Type 2 Diabetes Patients With CKD

By

Almost 40% of pre-dialysis patients with stage 4-5 CKD patients and type 2 diabetes had lab results suggesting low turnover bone disease.

Sign Up for Free e-newsletters